Скачать или смотреть James Rowe - CNS 2023 - Cambridge Biomedical Research Centre

About CNS2023
The 33rd annual Cambridge Neuroscience Seminar took place on Tuesday September 26th 2023 at Robinson College at the University of Cambridge. We used our annual meeting to highlight the strength in the interdisciplinary approach to tackling dementia and how collaboration, with the communal aim of understanding these diseases and identifying new treatments, is key.

Cambridge Biomedical Research Centre
Neurodegenerative Disease and Dementia Theme

Leadership: James Rowe and Caroline Williams-Gray

Website: https://cambridgebrc.nihr.ac.uk/resea...

The NIHR Cambridge BRC is part of the NIHR and hosted by Cambridge University Hospitals NHS Foundation Trust in partnership with the University of Cambridge, and includes a major commitment to neurodegenerative disease and dementia research. We bring together
the expertise and resources of both partners to support ‘translational research’, turning scientific discoveries into new ways to detect, treat and prevent disease. We work closely with other NIHR BRC’s and NHS
organisations in the Dementia Translational Research Collaboration (DTRC), together with universities, research councils, research charities, industry and of course patients and the public. Our Academic, Healthcare and Industry partnerships create a vibrant environment to train and mentor the next generation of research leaders and to work with patients, communities and the public to understand their research needs and priorities. The Neurodegenerative Disease and Dementia theme of the BRC works especially closely with the BRC themes for Mental Health, Imaging, Advanced Therapies, Nutrition obesity and metabolism, the Cambridge Brain Bank and CPFT. Our research teams are building research capacity and maximizing impact through experimental medicine studies and clinical trials that promote inclusion of under-served groups. For Alzheimer’s disease, Parkinson’s disease, Lewy Body Dementia, Vascular Dementia, Huntington’s disease, Frontotemporal dementias and Progressive Supranuclear Palsy we are:
1. Developing new tests for early detection of neurodegenerative disease, 2. Validating new treatment targets and accelerating clinical trials
3. Improving the research infrastructure for research and training
4. Preventing dementia in the context of co-existing diseases and frailty
5. Seeking to treat early and in those most at risk

Biography: James Rowe is a Professor of Cognitive Neurology at the University of Cambridge. He studies the mechanisms and treatment of neurodegenerative disorders, including frontotemporal dementia, Progressive Supranuclear Palsy and Alzheimer’s disease. He trained in medical sciences and experimental psychology at Cambridge, before clinical medicine at Oxford and a PhD at UCL. After specialist training in London and Copenhagen, he returned to Cambridge where he now directs the Centre for Frontotemporal Dementia, including its regional specialty clinics, and leads the Clinical program in the Centre for Parkinson-plus. He is Associate Director of Dementias Platform UK, and Chief Scientific Adviser to Alzheimers Research UK. James’ expertise in experimental medicine brings together multimodal brain imaging, genetics, psychopharmacology and computational models to transform the mechanistic understanding of human disease into new treatments and clinical trials.